The potential clinical applications of insulin-like growth factor-1 ligand in human breast cancer

Anticancer Research

Volumn 27, Issue 3 B, 2007, Pages 1617-1624

  Chong, Yoon Mann ^a,b   Subramanian, A ^a   Sharma, A K ^a   Mokbel, K ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

Breast cancer; Clinical applications; IGF 1; IGF 1 19 repeat allele; Insulin like growth factor 1; Oestrogen; Postmenopausal breast cancer; Premenopausal breast cancer; Prognosis; Review; Risk biomarkers

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; ESTROGEN; FENRETINIDE; INSULIN LIKE GROWTH FACTOR 1 LIGAND; LIGAND; PLACEBO; SOMATOMEDIN C; TAMOXIFEN; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER CELL; CANCER RISK; CANCER TISSUE; CARCINOGENESIS; CASE CONTROL STUDY; CELL STIMULATION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORRELATION ANALYSIS; DISEASE MARKER; DRUG MECHANISM; EVIDENCE BASED MEDICINE; GENETIC POLYMORPHISM; HUMAN; LOW DRUG DOSE; NONHUMAN; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT RESPONSE;

ANIMALS; BREAST NEOPLASMS; ESTROGENS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LIGANDS; MICE; POLYMORPHISM, GENETIC; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 34249291303     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Adams TE, Epa VC, Garrett TP and Ward CW: Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci 57: 1050-1093, 2000.
2. Al SW, Chong Y, Williams S, Sharma A and Mokbel K: The mRNA expression of IGF-1 and IGF-1R in human breast cancer: association with clinico-pathological parameters. J Carcinog 5: 16, 2006.
3. Allen NE, Roddam AW, Allen DS, Fentiman IS, Dos SS, I, Peto J, Holly JM and Key TJ: A prospective study of serum insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3 and breast cancer risk. Br J Cancer 92: 1283-1287, 2005.
4. Baserga R, Hongo A, Rubini M, Prisco M and Valentinis B: The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta 1332: F105-F126, 1997.
5. Bonanni B, Ramazzoto F, Franchi D et al: A randomised trial of fenretinide in HRT users using IGf-1 as a surrogate biomarker (abstract). Breast Cancer Res Treat 64: A152, 2000.
6. Bulun SE, Lin Z, Imir G, Amin S, Demura M, Yilmaz B, Martin R, Utsunomiya H, Thung S, Gurates B, Tamura M, Langoi D and Deb S: Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev 57: 359-383, 2005.
7. Chapman IM, Hartman ML, Pieper KS, Skiles EH, Pezzoli SS, Hintz RL and Thorner MO: Recovery of growth hormone release from suppression by exogenous insulin-like growth factor I (IGF-I): evidence for a suppressive action of free rather than bound IGF-I. J Clin Endocrinol Metab 83: 2836-2842, 1998.
8. Chong YM, Colston K, Jiang WG, Sharma AK and Mokbel K: The relationship between the insulin-like growth factor-1 system and the oestrogen metabolising enzymes in breast cancer tissue and its adjacent non-cancerous tissue. Breast Cancer Res Treat 99: 275-288, 2006.
9. Chong YM, Williams SL, Elkak A, Sharma AK and Mokbel K: Insulin-like growth factor 1 (IGF-1) and its receptor mRNA levels in breast cancer and adjacent non-neoplastic tissue. Anticancer Res 26: 167-173, 2006.
10. Colletti RB, Roberts JD, Devlin JT and Copeland KC: Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. Cancer Res 49: 1882-1884, 1989.
11. Comuzzie AG, Blangero J, Mahaney MC, Haffner SM, Mitchell BD, Stern MP and MacCluer JW: Genetic and environmental correlations among hormone levels and measures of body fat accumulation and topography. J Clin Endocrinol Metab 81: 597-600, 1996.
12. Coskun U, Gunel N, Sancak B, Gunel U, Onuk E, Bayram O, Yilmaz E, Candan S and Ozkan S: Significance of serum vascular endothelial growth factor, insulin-like growth factor-I levels and nitric oxide activity in breast cancer patients. Breast 12: 104-110, 2003.
13. Decensi A, Bonanni B, Guerrieri-Gonzaga A, Gandini S, Robertson C, Johansson H, Travaglini R, Sandri MT, Tessadrelli A, Farante G, Salinaro F, Bettega D, Barreca A, Boyle P, Costa A and Veronesi U: Biologic activity of tamoxifen at low doses in healthy women. J Natl Cancer Inst 90: 1461-1467, 1998.
14. Dupont J, Karas M and LeRoith D: The potentiation of estrogen on insulin-like growth factor I action in MCF-7 human breast cancer cells includes cell cycle components 1. J Biol Chem 275: 35893-35901, 2000.
15. Dupont WD and Page DL: Breast cancer risk associated with proliferative disease, age at first birth, and a family history of breast cancer. Am J Epidemiol 125: 769-779, 1987.
16. Ellis MJ, Jenkins S, Hanfelt J, Redington ME, Taylor M, Leek R, Siddle K and Harris A: Insulin-like growth factors in human breast cancer. Breast Cancer Res Treat 52: 175-184, 1998.
17. Eppler E, Zapf J, Bailer N, Falkmer UG, Falkmer S and Reinecke M: IGF-I in human breast cancer: low differentiation stage is associated with decreased IGF-I content. Eur J Endocrinol 146: 813-821, 2002.
18. Fabian CJ and Kimler BF: Chemoprevention for high-risk women: tamoxifen and beyond. Breast J 7: 311-320, 2001.
19. Friedl A, Jordan VC and Pollak M: Suppression of serum insulin-like growth factor-1 levels in breast cancer patients during adjuvant tamoxifen therapy. Eur J Cancer 29A: 1368-1372, 1993.
20. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C and Mulvihill JJ: Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81: 1879-1886, 1989.
21. Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K and Vogel V: Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 91: 1829-1846, 1999.
22. Gebauer G, Jager W and Lang N: mRNA expression of components of the insulin-like growth factor system in breast cancer cell lines, tissues and metastatic breast cancer cells. Anticancer Res 18: 1191-1195, 1998.
23. Geier A, Beery R, Haimsohn M and Karasik A: Insulin-like growth factor-1 inhibits cell death induced by anticancer drugs in the MCF-7 cells: involvement of growth factors in drug resistance. Cancer Invest 13: 480-486, 1995.
24. Giudice LC, Dsupin BA, Gargosky SE, Rosenfeld RG and Irwin JC: The insulin-like growth factor system in human peritoneal fluid: its effects on endometrial stromal cells and its potential relevance to endometriosis. J Clin Endocrinol Metab 79: 1284-1293, 1994.
25. Guerra FK, Eijan AM, Puricelli L, Alonso DF, Bal de Kier JE, Kornblihgtt AR, Charreau EH and Elizalde PV: Varying patterns of expression of insulin-like growth factors I and II and their receptors in murine mammary adenocarcinomas of different metastasizing ability. Int J Cancer 65: 812-820, 1996.
26. Guo YS, Jin GF, Houston CW, Thompson JC and Townsend CM Jr: Insulin-like growth factor-I promotes multidrug resistance in MCLM colon cancer cells. J Cell Physiol 175: 141-148, 1998.
27. Guvakova MA and Surmacz E: Overexpressed IGF-I receptors reduce estrogen growth requirements, enhance survival and promote E-cadherin-mediated cell-cell adhesion in human breast cancer cells. Exp Cell Res 231: 149-162, 1997.
28. Hadsell DL, Murphy KL, Bonnette SG, Reece N, Laucirica R and Rosen JM: Cooperative interaction between mutant p53 and des(1-3)IGF-I accelerates mammary tumorigenesis. Oncogene 19: 889-898, 2000.
29. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE and Pollak M: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351: 1393-1396, 1998.
30. Harrela M, Koistinen H, Kaprio J, Lehtovirta M, Tuomilehto J, Eriksson J, Toivanen L, Koskenvuo M, Leinonen P, Koistinen R and Seppala M: Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J Clin Invest 98: 2612-2615, 1996.
31. Hartmann BW, Lami T, Kirchengast S, Albrecht AE and Huber JC: Hormonal breast augmentation: prognostic relevance of insulin-like growth factor-I. Gynecol Endocrinol 12: 123-127, 1998.
32. Hartmann BW, Laml T, Kirchengast S, Albrecht AE and Huber JC: Hormonal breast augmentation: prognostic relevance of insulin-like growth factor-I. Gynecol Endocrinol 12: 123-127, 1998.
33. Holdaway IM, Mason BH, Lethaby AE, Singh V, Harvey VJ, Thompson PI and Evans BD: Serum insulin-like growth factor-I and insulin-like growth factor binding protein-3 following chemotherapy for advanced breast cancer. ANZ J Surg 73: 905-908, 2003.
34. Jernstrom H, Chu W, Vesprini D, Tao Y, Majeed N, Deal C, Pollak M and Narod SA: Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: implications for premenopausal breast cancer risk. Mol Genet Metab 72: 144-154, 2001.
35. Jernstrom H, Deal C, Wilkin F, Chu W, Tao Y, Majeed N, Hudson T, Narod SA and Pollak M: Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev 10: 377-384, 2001.
36. Jernstrom H and Olsson H: Breast size in relation to endogenous hormone levels, body constitution, and oral contraceptive use in healthy nulligravid women aged 19-25 years. Am J Epidemiol 145: 571-580, 1997.
37. Jernstrom H, Sandberg T, Bageman E, Borg A and Olsson H: Insulin-like growth factor-1 (IGF-1) genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating IGF-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families. Br J Cancer 92: 857-866, 2005.
38. Jernstrom H, Sandberg T, Bageman E, Borg A and Olsson H: Insulin-like growth factor-1 (IGF-1) genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating IGF-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families. Br J Cancer 92: 857-866, 2005.
39. Kaaks R, Lundin E, Rinaldi S, Manjer J, Biessy C, Soderberg S, Lenner P, Janzon L, Riboli E, Berglund G and Hallmans G: Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden. Cancer Causes Control 13: 307-316, 2002.
40. Kao PC, Matheny AP Jr and Lang CA: Insulin-like growth factor-I comparisons in healthy twin children. J Clin Endocrinol Metab 78: 310-312, 1994.
41. Keinan-Boker L, Bueno De Mesquita HB, Kaaks R, Van Gils CH, Van Noord PA, Rinaldi S, Riboli E, Seidell JC, Grobbee DE and Peeters PH: Circulating levels of insulin-like growth factor I, its binding proteins -1,-2, -3, C-peptide and risk of postmenopausal breast cancer. Int J Cancer 106: 90-95, 2003.
42. Kleinman D, Karas M, Roberts CT Jr, LeRoith D, Phillip M, Segev Y, Levy J and Sharoni Y: Modulation of insulin-like growth factor I (IGF-I) receptors and membrane-associated IGF-binding proteins in endometrial cancer cells by estradiol. Endocrinology 136: 2531-2537, 1995.
43. Krajcik RA, Borofsky ND, Massardo S and Orentreich N: Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer. Cancer Epidemiol Biomarkers Prev 11: 1566-1573, 2002.
44. Kudoh M, Susaki Y, Ideyama Y, Nanya T, Mori M and Shikama H: Inhibitory effects of a novel aromatase inhibitor, YM511, on growth of endometrial explants and insulin-like growth factor-I gene expression in rats with experimental endometriosis. J Steroid Biochem Mol Biol 63: 75-80, 1997.
45. LeRoith D and Roberts CT Jr: The insulin-like growth factor system and cancer. Cancer Lett 195: 127-137, 2003.
46. Li BD, Khosravi MJ, Berkel HJ, Diamandi A, Dayton MA, Smith M and Yu H: Free insulin-like growth factor-I and breast cancer risk. Int J Cancer 91: 736-739, 2001.
47. Long L, Rubin R, Baserga R and Brodt P: Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor. Cancer Res 55: 1006-1009, 1995.
48. Lonning PE, Hall K, Aakvaag A and Lien EA: Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Res 52: 4719-4723, 1992.
49. Maskarinec G, Williams AE and Kaaks R: A cross-sectional investigation of breast density and insulin-like growth factor I. Int J Cancer 107: 991-996, 2003.
50. Missmer SA, Haiman CA, Hunter DJ, Willett WC, Colditz GA, Speizer FE, Pollak MN and Hankinson SE: A sequence repeat in the insulin-like growth factor-1 gene and risk of breast cancer. Int J Cancer 100: 332-336, 2002.
51. Mizukami Y, Nonomura A, Yamada T, Kurumaya H, Hayashi M, Koyasaki N, Taniya T, Noguchi M, Nakamura S and Matsubara F: Immunohistochemical demonstration of growth factors, TGF-alpha, TGF-beta, IGF-I and neu oncogene product in benign and malignant human breast tissues. Anticancer Res 10: 1115-1126, 1990.
52. Moschos SJ and Mantzoros CS: The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology 63: 317-332, 2002.
53. Muti P, Quattrin T, Grant BJ, Krogh V, Micheli A, Schunemann HJ, Ram M, Freudenheim JL, Sieri S, Trevisan M and Berrino F: Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 11: 1361-1368, 2002.
54. Ng ST, Zhou J, Adesanya OO, Wang J, LeRoith D and Bondy CA: Growth hormone treatment induces mammary gland hyperplasia in aging primates. Nat Med 3: 1141-1144, 1997.
55. Nicholson RI, Hutcheson IR, Knowlden JM, Jones HE, Harper ME, Jordan N, Hiscox SE, Barrow D and Gee JM: Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clin Cancer Res 10: 346S-354S, 2004.
56. Nicholson RI and Johnston SR: Endocrine therapy - current benefits and limitations. Breast Cancer Res Treat 93(Suppl 1): S3-10, 2005.
57. Nicholson RI, Staka C, Boyns F, Hutcheson IR and Gee JM: Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy. Endocr Relat Cancer 11: 623-641, 2004.
58. Pearson Oh and Ray BS: Results of hypophysectomy in the treatment of metastatic mammary carcinoma. Cancer 12: 85-92, 1959.
59. Peyrat JP, Bonneterre J, Hecquet B, Vennin P, Louchez MM, Fournier C, Lefebvre J and Demaille A: Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer 29A: 492-497, 1993.
60. Pollak M, Costantino J, Polychronakos C, Blauer SA, Guyda H, Redmond C, Fisher B and Margolese R: Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients. J Natl Cancer Inst 82: 1693-1697, 1990.
61. Pollak MN: Endocrine effects of IGF-I on normal and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention. Breast Cancer Res Treat 47: 209-217, 1998.
62. Resnicoff M and Baserga R: The role of the insulin-like growth factor I receptor in transformation and apoptosis. Ann N Y Acad Sci 842: 76-81, 1998.
63. Richards RG, Walker MP, Sebastian J and DiAugustine RP: Insulin-like growth factor-1 (IGF-1) receptor-insulin receptor substrate complexes in the uterus. Altered signaling response to estradiol in the IGF-1(m/m) mouse. J Biol Chem 273: 11962-11969, 1998.
64. Rollison DE, Newschaffer CJ, Tao Y, Pollak M and Helzlsouer KJ: Premenopausal levels of circulating insulin-like growth factor I and the risk of postmenopausal breast cancer. Int J Cancer 118: 1279-1284, 2006.
65. Rosen CJ, Kurland ES, Vereault D, Adler RA, Rackoff PJ, Craig WY, Witte S, Rogers J and Bilezikian JP: Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-I gene: implications for genetic studies of bone mineral density. J Clin Endocrinol Metab 83: 2286-2290, 1998.
66. Ruan W, Catanese V, Wieczorek R, Feldman M and Kleinberg DL: Estradiol enhances the stimulatory effect of insulin-like growth factor-I (IGF-I) on mammary development and growth hormone-induced IGF-I messenger ribonucleic acid. Endocrinology 136: 1296-1302, 1995.
67. Schernhammer ES, Holly JM, Pollak MN and Hankinson SE: Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 14: 699-704, 2005.
68. Shi R, Yu H, McLarty J and Glass J: IGF-I and breast cancer: a meta-analysis. Int J Cancer 111: 418-423, 2004.
69. Sjogren K, Liu JL, Blad K, Skrtic S, Vidal O, Wallenius V, LeRoith D, Tornell J, Isaksson OG, Jansson JO and Ohlsson C: Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci USA 96: 7088-7092, 1999.
70. Stewart AJ, Johnson MD, May FE and Westley BR: Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J Biol Chem 265: 21172-21178, 1990.
71. Teruel T, Valverde AM, Benito M and Lorenzo M: Insulin-like growth factor I and insulin induce adipogenic-related gene expression in fetal brown adipocyte primary cultures. Biochem J 319(Pt 2): 627-632, 1996.
72. Thissen JP, Ketelslegers JM and Underwood LE: Nutritional regulation of the insulin-like growth factors. Endocr Rev 15: 80-101, 1994.
73. Toniolo P, Bruning PF, Akhmedkhanov A, Bonfrer JM, Koenig KL, Lukanova A, Shore RE and Zeleniuch-Jacquotte A: Serum insulin-like growth factor-I and breast cancer. Int J Cancer 88: 828-832, 2000.
74. Toropainen E, Lipponen P and Syrjanen K: Expression of insulin-like growth factor I (IGF-I) in female breast cancer as related to established prognostic factors and long-term prognosis. Eur J Cancer 31A: 1443-1448, 1995.
75. Torrisi R, Decensi A, Formelli F, Camerini T and De PG: Chemoprevention of breast cancer with fenretinide. Drugs 61: 909-918, 2001.
76. Umayahara Y, Kawamori R, Watada H, Imano E, Iwama N, Morishima T, Yamasaki Y, Kajimoto Y and Kamada T: Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer. J Biol Chem 269: 16433-16442, 1994.
77. Vadgama JV, Wu Y, Datta G, Khan H and Chillar R: Plasma insulin-like growth factor-I and serum IGF-binding protein 3 can be associated with the progression of breast cancer, and predict the risk of recurrence and the probability of survival in African-American and Hispanic women. Oncology 57: 330-340, 1999.
78. Valverde AM, Lorenzo M, Navarro P and Benito M: Phosphatidylinositol 3-kinase is a requirement for insulin-like growth factor I-induced differentiation, but not for mitogenesis, in fetal brown adipocytes. Mol Endocrinol 11: 595-607, 1997.
79. Voskuil DW, Bosma A, Vrieling A, Rookus MA and 't Veer LJ: Insulin-like growth factor (IGF)-system mRNA quantities in normal and tumor breast tissue of women with sporadic and familial breast cancer risk. Breast Cancer Res Treat 84: 225-233, 2004.
80. Wennbo H and Tornell J: The role of prolactin and growth hormone in breast cancer. Oncogene 19: 1072-1076, 2000.
81. Wu Y, Cui K, Miyoshi K, Hennighausen L, Green JE, Setser J, LeRoith D and Yakar S: Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res 63: 4384-4388, 2003.
82. Yee D, Paik S, Lebovic GS, Marcus RR, Favoni RE, Cullen KJ, Lippman ME and Rosen N: Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol 3: 509-517, 1989.
83. Yu H, Levesque MA, Khosravi MJ, Papanastasiou-Diamandi A, Clark GM and Diamandis EP: Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer. Br J Cancer 74: 1242-1247, 1996.
84. Yu H and Rohan T: Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92: 1472-1489, 2000.